Rallybio Corp (RLYB)

06:33 AM

Is Rallybio Corporation a good long term investmentSky-high profits - jammulinksnews.com

06:33 AM

06:15 AM

Rallybio Corporation Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional

06:15 AM

Jul 22, 2025

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN

Jul 22, 2025

Jul 22, 2025

What analysts say about Rallybio Corporation stockHigh-octane gains - jammulinksnews.com

Jul 22, 2025

Jul 20, 2025

What drives Rallybio Corporation stock priceUnmatched market gains - printweek.in

Jul 20, 2025

Jul 19, 2025

Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN

Jul 19, 2025

Jul 18, 2025

10 Best Small Cap AI Stocks to Buy According to Analysts - Insider Monkey

Jul 18, 2025

Jul 17, 2025

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN

Jul 17, 2025

Jul 16, 2025

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com

Jul 16, 2025

Jul 15, 2025

What makes Rallybio Corporation stock price move sharplyFree Best Performing Stock Alerts - Newser

Jul 15, 2025

Jul 15, 2025

Why Rallybio Corporation stock attracts strong analyst attentionFree Join Group - Newser

Jul 15, 2025

Jul 15, 2025

How Rallybio Corporation stock performs during market volatilityCarefully Curated High Return Stocks - Newser

Jul 15, 2025

Jul 13, 2025

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - MSN

Jul 13, 2025

Jul 11, 2025

Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN

Jul 11, 2025

Jul 10, 2025

We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st

Jul 10, 2025

Jul 09, 2025

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey

Jul 09, 2025

Jul 09, 2025

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance

Jul 09, 2025

Jul 09, 2025

Rallybio sells REV102 programme to Recursion for up to $25m - Pharmaceutical Business review -

Jul 09, 2025

Jul 09, 2025

Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal - AInvest

Jul 09, 2025

Jul 09, 2025

Rallybio sells HPP treatment program to Recursion for up to $25 million By Investing.com - Investing.com South Africa

Jul 09, 2025

Jul 08, 2025

Rallybio sells HPP treatment program to Recursion for up to $25 million - Investing.com Nigeria

Jul 08, 2025

Jul 08, 2025

Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize

Jul 08, 2025

Jul 08, 2025

Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio - Investing.com India

Jul 08, 2025

Jul 08, 2025

Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize

Jul 08, 2025

Jul 08, 2025

Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - MarketScreener

Jul 08, 2025

Jul 08, 2025

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - citybiz

Jul 08, 2025

Jul 08, 2025

RallyBio - Hartford Business Journal

Jul 08, 2025

Jul 08, 2025

Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal

Jul 08, 2025

Jul 08, 2025

Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga

Jul 08, 2025

Jul 08, 2025

Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement - TipRanks

Jul 08, 2025

Jul 08, 2025

Rallybio shifts gears, cashing out of Recursion pact to extend runway - Fierce Biotech

Jul 08, 2025

Jul 08, 2025

Recursion Pharmaceuticals Acquires Full Interest in Joint Hypophosphatasia Candidate From Rallybio - MarketScreener

Jul 08, 2025

Jul 08, 2025

Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha

Jul 08, 2025

Jul 08, 2025

Rallybio sells interest in REV102 program to Recursion Pharmaceuticals - grafa.com

Jul 08, 2025

Jul 08, 2025

Rallybio Sells REV102 Program to Recursion Pharmaceuticals - TipRanks

Jul 08, 2025